Genmab has linked an antibody-drug conjugate (ADC) to median progression-free survival (PFS) of 9.5 months, leading TD Cowen ...

When Xaira Therapeutics debuted in 2024 with a gobsmacking $1 billion in funding, a natural expectation would have been for a ...

Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...

Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...

As Foghorn digested the end of the Lilly partnership, the biotech said it was laying off 40% of its workforce, while “further ...

A more subdued volume of biopharma layoffs continued into the third quarter of 2026, validating predictions that the sector ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...

The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...

A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary ...

The revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has ...

A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, ...